Cargando…
Managing chronic lymphocytic leukemia in 2020: an update on recent clinical advances with a focus on BTK and BCL-2 inhibitors
The therapeutic landscape of chronic lymphocytic leukemia (CLL) underwent a paradigm shift in 2014 with the approval of ibrutinib, which binds covalently to the C481 residue of Bruton’s tyrosine kinase (BTK) and irreversibly inhibits it. A number of large, phase 3 trials conducted in both the frontl...
Autores principales: | Bose, Prithviraj, Gandhi, Varsha |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Faculty Opinions Ltd
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7946394/ https://www.ncbi.nlm.nih.gov/pubmed/33718939 http://dx.doi.org/10.12703/r/10-22 |
Ejemplares similares
-
Recent therapeutic advances in chronic lymphocytic leukemia
por: Bose, Prithviraj, et al.
Publicado: (2017) -
Combining BTK inhibitors with BCL2 inhibitors for treating chronic lymphocytic leukemia and mantle cell lymphoma
por: Zhang, Jing, et al.
Publicado: (2022) -
Selecting the optimal BTK inhibitor therapy in CLL: rationale and
practical considerations
por: Lovell, Alexandra R., et al.
Publicado: (2022) -
BTK Inhibitors in Chronic Lymphocytic Leukemia: Biological Activity and Immune Effects
por: Palma, Marzia, et al.
Publicado: (2021) -
PB1912: BTK AND PLCG2 GENE MUTATIONS IN CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS WITH RESISTANCE TO COVALENT BTK INHIBITOR
por: Likold, Ekaterina, et al.
Publicado: (2023)